Skip to main content

Table 1 Patient characteristics according to diagnosis

From: Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease

  Age, years Sex, F/M (% female) MMSE score at baseline CSF Aβ42 (pg/ml) CSF tau (pg/ml) CSF p-tau (pg/ml)
Control subjects, n = 40 64.5 ± 8.2 19/21 (48%) 28.3 ± 1.7 1086 ± 161 228 ± 64 40 ± 9
MCI, n = 40 64.5 ± 8.1 19/21 (48%) 26.3 ± 2.3* 839 ± 297* 481 ± 256* 69 ± 33*
 sMCI, n = 23 63.7 ± 7.4 11/12 (48%) 26.7 ± 2.0 941 ± 306 338 ± 182 51 ± 21
 MCI-ADa, n = 14 65.6 ± 9.0 7/7 (50%) 25.9 ± 2.7 632 ± 84*,$ 722 ± 186*,$ 99 ± 28*,$
AD dementia, n = 40 64.6 ± 8.1 19/21 (48%) 21.6 ± 3.9* 640 ± 91*,‡,$ 740 ± 433*,‡,$ 94 ± 47*,‡,$
  1. Abbreviations: Aβ 42 Amyloid-β 1–42, AD Alzheimer’s disease, CSF Cerebrospinal fluid, MCI Mild cognitive impairment, MMSE Mini Mental State Examination, p-tau Tau phosphorylated at threonine 181, sMCI Stable mild cognitive impairment
  2. Data are displayed as mean ± SD unless otherwise indicated. Analysis of variance with post hoc Bonferroni corrections or chi-square tests were used when appropriate. CSF Aβ42, total tau, and p-tau were logarithmically transformed for the analyses because of skewed values; in the table, crude values are shown
  3. aMCI patients progressing to another form of dementia (n=3) were excluded
  4. *p < 0.01 vs controls
  5. p < 0.05 vs controls
  6. p < 0.01 vs all MCI patients
  7. $p < 0.01 vs sMCI patients